• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗磷脂综合征不同临床类型中的标准和非标准抗磷脂抗体

Criteria and non-criteria anti-phospholipid antibodies in the different clinical forms of antiphospholipid syndrome.

作者信息

Cabrera-Marante Oscar, Pleguezuelo Daniel, Garcinuño Sara, Naranjo Laura, Díaz-Simón Raquel, Gil-Etayo Francisco Javier, Zafra Denis, Lozano-Morillo Fernando, Morillas Luis, Abad Magdalena, Villar Olga, Martínez-Salio Antonio, Lizarraga-Hurtado Tito Leoncio, Paz-Artal Estela, Serrano Antonio, Serrano Manuel

机构信息

Immunology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.

Facultad HM de Ciencias de la Salud, Universidad Camilo José Cela, Villanueva de la Cañada, Madrid, Spain.

出版信息

Front Immunol. 2025 Aug 1;16:1636171. doi: 10.3389/fimmu.2025.1636171. eCollection 2025.

DOI:10.3389/fimmu.2025.1636171
PMID:40821829
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12354381/
Abstract

INTRODUCTION

Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by thrombotic symptoms (venous, arterial, or small vessels) and/or gestational morbidity in patients carrying antiphospholipid antibodies (aPLs). Criteria aPLs include anti-cardiolipin antibodies, anti-beta 2 glycoprotein I (aB2GPI) antibodies of the IgG or IgM isotypes, and lupus anticoagulant (LA). However, there are aPLs that are associated with APS events but are not included in the criteria (extra-criteria). The aim of this study is to evaluate the prevalence and association of criteria and extra-criteria aPLs with APS clinical events.

METHODS

A total of 838 patients with clinical manifestations of APS were studied. In total, 715 presented with vascular manifestations, and 130 presented with obstetric morbidity. We measured levels of criteria aPLs, and the extra-criteria aPLs determined were anti-phosphatidylserine/prothrombin (aPS/PT) of IgG and IgM isotypes and aB2GPI IgA.

RESULTS

Classic aPL, aPS/PT, and aB2GPI IgA positivity showed a significant and independent association with thrombosis (OR: 2.40, 2.36, and 2.53 respectively). IgA aB2GP1 was the only aPL significantly associated with the five types of thrombotic events (venous thrombosis, pulmonary embolism, stroke, acute myocardial infarction, and arterial thrombosis). Regarding obstetric APS, the most relevant antibodies were classic aPL of IgM isotype (OR: 36.04) and aPS/PT of both isotypes (OR: 4.4). The other aPL studied did not show association in multivariate analysis.

DISCUSSION

The degree of clinical association for each group of aPLs was different depending on the form of presentation (vascular or obstetric) and the presence or absence of autoimmune diseases. Moreover, a fair level of agreement between LA and aPS/PT positivity was found; therefore, aPS/PT should not be referred to as a surrogate marker of LA.

摘要

引言

抗磷脂综合征(APS)是一种全身性自身免疫性疾病,其特征为携带抗磷脂抗体(aPL)的患者出现血栓形成症状(静脉、动脉或小血管)和/或妊娠并发症。标准aPL包括抗心磷脂抗体、IgG或IgM同种型的抗β2糖蛋白I(aB2GPI)抗体以及狼疮抗凝物(LA)。然而,存在一些与APS事件相关但未纳入标准的aPL(标准外)。本研究的目的是评估标准aPL和标准外aPL与APS临床事件的患病率及相关性。

方法

共研究了838例有APS临床表现的患者。其中,715例有血管表现,130例有产科并发症。我们检测了标准aPL的水平,所确定的标准外aPL为IgG和IgM同种型的抗磷脂酰丝氨酸/凝血酶原(aPS/PT)以及aB2GPI IgA。

结果

经典aPL、aPS/PT和aB2GPI IgA阳性与血栓形成呈显著独立相关(OR分别为:2.40、2.36和2.53)。IgA aB2GP1是唯一与五种血栓形成事件(静脉血栓形成、肺栓塞、中风、急性心肌梗死和动脉血栓形成)显著相关的aPL。关于产科APS,最相关的抗体是IgM同种型的经典aPL(OR:36.04)和两种同种型的aPS/PT(OR:4.4)。在多变量分析中,所研究的其他aPL未显示相关性。

讨论

每组aPL的临床关联程度因表现形式(血管性或产科性)以及自身免疫性疾病的有无而异。此外,发现LA和aPS/PT阳性之间有相当程度的一致性;因此,aPS/PT不应被视为LA的替代标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27db/12354381/874ad0ef05ad/fimmu-16-1636171-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27db/12354381/a0c08e9de479/fimmu-16-1636171-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27db/12354381/d4b74751ead3/fimmu-16-1636171-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27db/12354381/874ad0ef05ad/fimmu-16-1636171-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27db/12354381/a0c08e9de479/fimmu-16-1636171-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27db/12354381/d4b74751ead3/fimmu-16-1636171-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27db/12354381/874ad0ef05ad/fimmu-16-1636171-g003.jpg

相似文献

1
Criteria and non-criteria anti-phospholipid antibodies in the different clinical forms of antiphospholipid syndrome.抗磷脂综合征不同临床类型中的标准和非标准抗磷脂抗体
Front Immunol. 2025 Aug 1;16:1636171. doi: 10.3389/fimmu.2025.1636171. eCollection 2025.
2
Thrombotic Antiphospholipid Syndrome: Recurrent Thromboses.血栓形成性抗磷脂综合征:复发性血栓形成
Dokl Biochem Biophys. 2025 May 11. doi: 10.1134/S1607672925700152.
3
Antibody profiles in the mosaic of 'seronegative' APS syndrome.“血清阴性”APS 综合征的镶嵌体中的抗体谱。
Clin Exp Immunol. 2024 Nov 12;218(3):275-282. doi: 10.1093/cei/uxae079.
4
Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies.抗血小板和抗凝药物用于抗磷脂抗体个体血栓形成的一级预防。
Cochrane Database Syst Rev. 2018 Jul 13;7(7):CD012534. doi: 10.1002/14651858.CD012534.pub2.
5
Prevalence of aPhosphatidylserine/prothrombin antibodies and association with antiphospholipid antibody profiles in patients with antiphospholipid syndrome: A systematic review and meta-analysis.抗磷脂综合征患者中 Phosphatidylserine/prothrombin 抗体的流行情况及其与抗磷脂抗体谱的关系:系统评价和荟萃分析。
Thromb Res. 2022 Jun;214:106-114. doi: 10.1016/j.thromres.2022.04.021. Epub 2022 May 2.
6
Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis.成人系统性红斑狼疮患者以外的抗磷脂抗体类型与静脉和动脉血栓形成风险:系统评价和荟萃分析。
Autoimmun Rev. 2014 Jun;13(6):595-608. doi: 10.1016/j.autrev.2013.11.004. Epub 2014 Jan 11.
7
Long-Term Follow-Up of Patients With Positive Antiphospholipid Antibodies After Fetal Death: Five Typical Cases From a Prospective Cohort Study.胎儿死亡后抗磷脂抗体阳性患者的长期随访:一项前瞻性队列研究中的五个典型病例
Immun Inflamm Dis. 2025 Feb;13(2):e70158. doi: 10.1002/iid3.70158.
8
Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review.抗凝血酶原 (aPT) 和抗磷脂酰丝氨酸/凝血酶原 (aPS/PT) 抗体与抗磷脂综合征中的血栓形成风险。系统评价。
Thromb Haemost. 2014 Feb;111(2):354-64. doi: 10.1160/TH13-06-0509. Epub 2013 Oct 31.
9
Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review.检查抗磷脂综合征患者中非标准抗磷脂抗体的流行情况:系统评价。
Rheumatology (Oxford). 2015 Nov;54(11):2042-50. doi: 10.1093/rheumatology/kev226. Epub 2015 Jul 7.
10
Added value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome: lessons learned from year-long routine measurements.非标准抗磷脂抗体对抗磷脂综合征的附加价值:来自长达一年的常规测量中得到的经验教训。
Clin Rheumatol. 2019 Feb;38(2):371-378. doi: 10.1007/s10067-018-4251-7. Epub 2018 Aug 11.

本文引用的文献

1
Antiphospholipid antibody testing.抗磷脂抗体检测。
Med Clin (Barc). 2024 Aug;163 Suppl 1:S4-S9. doi: 10.1016/j.medcli.2024.06.002.
2
Quantification of Antiphospholipid Antibodies: The Importance of Using an Appropriate Methodology for Each Clinical Profile.抗磷脂抗体的定量检测:针对不同临床特征选择合适方法学的重要性。
Int J Mol Sci. 2023 Dec 12;24(24):17373. doi: 10.3390/ijms242417373.
3
The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.2023年美国风湿病学会/欧洲抗风湿病联盟抗磷脂综合征分类标准。
Arthritis Rheumatol. 2023 Oct;75(10):1687-1702. doi: 10.1002/art.42624. Epub 2023 Aug 28.
4
Multiple autoimmune syndrome: Clinical, immunological and genotypic characterization.多重自身免疫综合征:临床、免疫学及基因特征
Eur J Intern Med. 2023 Oct;116:119-130. doi: 10.1016/j.ejim.2023.06.020. Epub 2023 Jun 28.
5
Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ('Registry').抗磷脂抗体阳性患者的妊娠结局:来自抗磷脂抗体综合征临床研究和国际网络联盟(APS ACTION)临床数据库和存储库(“注册中心”)的前瞻性结果。
Lupus Sci Med. 2022 Jun;9(1). doi: 10.1136/lupus-2021-000633.
6
Evaluation of Frequency, Clinical Correlation, and Antibodies Confirmation Profile in Patients with Suspected Antiphospholipid Syndrome.疑似抗磷脂综合征患者的频率、临床相关性及抗体确认情况评估
TH Open. 2021 Oct 19;5(4):e470-e478. doi: 10.1055/s-0041-1736289. eCollection 2021 Oct.
7
Anti-Phospholipid Antibodies and COVID-19 Thrombosis: A Co-Star, Not a Supporting Actor.抗磷脂抗体与新冠病毒感染相关血栓形成:主角,而非配角。
Biomedicines. 2021 Jul 27;9(8):899. doi: 10.3390/biomedicines9080899.
8
Management of Pregnancy in Women of Advanced Maternal Age: Improving Outcomes for Mother and Baby.高龄孕产妇的孕期管理:改善母婴结局
Int J Womens Health. 2021 Aug 10;13:751-759. doi: 10.2147/IJWH.S283216. eCollection 2021.
9
Anti-Phosphatidylserine/Prothrombin Antibodies in Healthy Women with Unexplained Recurrent Pregnancy Loss.不明原因复发性流产健康女性中的抗磷脂酰丝氨酸/凝血酶原抗体
J Clin Med. 2021 May 13;10(10):2094. doi: 10.3390/jcm10102094.
10
Presence of Extra-Criteria Antiphospholipid Antibodies Is an Independent Risk Factor for Ischemic Stroke.存在额外标准抗磷脂抗体是缺血性中风的独立危险因素。
Front Cardiovasc Med. 2021 May 3;8:665741. doi: 10.3389/fcvm.2021.665741. eCollection 2021.